This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Surveillance

Understanding evolving resistance patterns is a key element in the quest to limit the rise of AMR.1

Antimicrobial Testing Leadership and Surveillance (ATLAS)

In 2017, Pfizer combined two global resistance surveillance programmes and launched the Antimicrobial Testing Leadership and Surveillance (ATLAS) website. It's one of the largest AMR surveillance programs in the world and has open access to healthcare workers, researchers and the global health community supporting easy access to critical resistance information. The system closely monitors global, regional and local resistance trends, allowing tracking of resistance and the main features include antimicrobial susceptibility geographic heat maps. ATLAS contains 15 years of continuous bacterial surveillance data, with more than 800 sites from over 75 countries. The data is updated every 6-8 months. ATLAS also contains 9 years of continuous fungal surveillance data, with more than 138 sites across over 40 countries.2

Pfizer and Wellcome Launch Surveillance Programme to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa3

Pfizer and Wellcome have recently announced the launch of a multi-year, public-private research collaboration with the governments of Ghana, Kenya, Malawi and Uganda to track resistance patterns and better understand the burden of antimicrobial resistance (AMR) on patients living in low and middle-income countries.

This first-of-its kind partnership – known as Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR) - will provide governments and health authorities with comprehensive data in four sub-Saharan African countries where there is a high burden of infectious diseases, insufficient data and lack of capacity to implement critically needed infection prevention and control programmes.

BSAC Resistance Surveillance Project

Specifically in the UK, Pfizer supported the BSAC Resistance Surveillance Project, which was a well-established program designed to provide long-term surveillance of antimicrobial resistance. Data is available for the last 20 years for an extensive list of bacterial pathogens.4

Access to Medicine Foundation: AMR Benchmark Report

Our surveillance efforts were recognised by the 2020 AMR Benchmark report. Pfizer were recognised as the first company to share raw data on resistance collected via our open-access ATLAS surveillance program.5

Educational Resources

We have a variety of educational resources aimed at supporting Healthcare Professsionals looking to enhance their knowledge of AMR and Stewardship.

Access resources

Pfizer's ATLAS Website

Sign up or login to Pfizer's ATLAS website

Sign in here

See how Pfizer's work in Stewardship & Surveillance ranked in the recent AMR Benchmark report

 AMR Benchmark report

References
  1. Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. May 2016. Available at: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf [Last Accessed July 2020]​
  2. Pfizer. Antimicrobial Testing Leadership and Surveillance. Available at: https://atlas-surveillance.com [Last Accessed July 2020]​
  3. Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa. Available at: https://www.pfizer.co.uk/pfizer-and-wellcome-launch-surveillance-programme-combat-growing-threat-antimicrobial-resistance-sub [Last Accessed July 2020]​
  4. The British Society for Antimicrobial Chemotherapy. Resistance Surveillance project. Available at: http://www.bsacsurv.org/ [Last Accessed July 2020]
  5. Access to Medicine Foundation. Antimicrobial resistance benchmark 2020. Available at: https://accesstomedicinefoundation.org/media/uploads/downloads/5f3f76733efaa_Antimicrobial_Resistance_Benchmark_2020.pdf [Last accessed July 2020].​
PP-AIP-GBR-0800. September 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No